ICER Misses the Numbers That Matter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the
cost-effectiveness of breakthrough drugs for cystic fibrosis.
But their analysis overlooks key points.
Categorized in: Analysis
Recent Blog Posts
Knocking Down Pneumococcal Disease
January 27, 2022
What it Takes to Treat Migraine
January 25, 2022
CVS Caremark “Switch” Puts Heart Patients at Risk
January 20, 2022